Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2019 2
2020 2
2021 1
2022 6
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Cost-effectiveness analysis of HIV pre-exposure prophylaxis in Japan.
Mizushima D, Nagai Y, Mezzio D, Harada K, Piao Y, Barnieh L, El Moustaid F, Cawson M, Taniguchi T. Mizushima D, et al. Among authors: el moustaid f. J Med Econ. 2023 Jan-Dec;26(1):886-893. doi: 10.1080/13696998.2023.2233824. J Med Econ. 2023. PMID: 37421417 Free article.
The Role of Vector Trait Variation in Vector-Borne Disease Dynamics.
Cator LJ, Johnson LR, Mordecai EA, Moustaid FE, Smallwood TRC, LaDeau SL, Johansson MA, Hudson PJ, Boots M, Thomas MB, Power AG, Pawar S. Cator LJ, et al. Among authors: moustaid fe. Front Ecol Evol. 2020 Jul;8:189. doi: 10.3389/fevo.2020.00189. Epub 2020 Jul 10. Front Ecol Evol. 2020. PMID: 32775339 Free PMC article.
The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial.
Perales MA, Kuruvilla J, Snider JT, Vadgama S, Blissett R, El-Moustaid F, Smith NJ, Patel AR, Johnston PB. Perales MA, et al. Among authors: el moustaid f. Transplant Cell Ther. 2022 Nov;28(11):750.e1-750.e6. doi: 10.1016/j.jtct.2022.08.010. Epub 2022 Aug 12. Transplant Cell Ther. 2022. PMID: 35970302 Free PMC article.
Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer.
Elsea D, Fan L, Mihai A, Moustaid FE, Simmons D, Monberg M, Muston D. Elsea D, et al. Among authors: moustaid fe. Pharmacoecon Open. 2022 Nov;6(6):811-822. doi: 10.1007/s41669-022-00338-2. Epub 2022 Aug 29. Pharmacoecon Open. 2022. PMID: 36036344 Free PMC article.
Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer.
Elsea D, Fan L, Mihai A, Moustaid FE, Simmons D, Monberg M, Muston D. Elsea D, et al. Among authors: moustaid fe. Pharmacoecon Open. 2022 Nov;6(6):899. doi: 10.1007/s41669-022-00372-0. Pharmacoecon Open. 2022. PMID: 36107308 Free PMC article. No abstract available.
15 results